SG11202109997PA - Novel azaindole derivative - Google Patents

Novel azaindole derivative

Info

Publication number
SG11202109997PA
SG11202109997PA SG11202109997PA SG11202109997PA SG 11202109997P A SG11202109997P A SG 11202109997PA SG 11202109997P A SG11202109997P A SG 11202109997PA SG 11202109997P A SG11202109997P A SG 11202109997PA
Authority
SG
Singapore
Prior art keywords
azaindole derivative
novel azaindole
novel
derivative
azaindole
Prior art date
Application number
Other languages
English (en)
Inventor
Gen Watanabe
Toshiharu Morimoto
Akira Iwata
Hirotaka Sasaki
Takahisa Ogamino
Kosuke Usuda
Ayumu Okuda
Hiroyuki Ishiwata
Yuichiro Tabunoki
Keigo Nishii
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of SG11202109997PA publication Critical patent/SG11202109997PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202109997P 2019-03-29 2020-03-30 Novel azaindole derivative SG11202109997PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019068233 2019-03-29
PCT/JP2020/014475 WO2020203950A1 (ja) 2019-03-29 2020-03-30 新規アザインドール誘導体

Publications (1)

Publication Number Publication Date
SG11202109997PA true SG11202109997PA (en) 2021-10-28

Family

ID=72668977

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109997P SG11202109997PA (en) 2019-03-29 2020-03-30 Novel azaindole derivative

Country Status (10)

Country Link
US (1) US20220162206A1 (enrdf_load_stackoverflow)
EP (1) EP3950063A4 (enrdf_load_stackoverflow)
JP (1) JPWO2020203950A1 (enrdf_load_stackoverflow)
KR (1) KR20210146320A (enrdf_load_stackoverflow)
CN (1) CN113613729A (enrdf_load_stackoverflow)
BR (1) BR112021019050A2 (enrdf_load_stackoverflow)
CA (1) CA3134937A1 (enrdf_load_stackoverflow)
MX (1) MX2021011923A (enrdf_load_stackoverflow)
SG (1) SG11202109997PA (enrdf_load_stackoverflow)
WO (1) WO2020203950A1 (enrdf_load_stackoverflow)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288918A (en) * 1992-09-29 1994-02-22 Union Carbide Chemicals & Plastics Technology Corporation Hydroformylation process
US5767321A (en) * 1995-12-06 1998-06-16 Union Carbide Chemicals & Plastics Technology Corporation Metal-ligand complex catalyzed processes
AU2004308299B2 (en) 2003-12-19 2011-11-24 Plexxikon, Inc. Compounds and methods for development of Ret modulators
EP1755597A2 (en) 2004-06-17 2007-02-28 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
EP2241333A1 (en) 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 csf-1r에 대한 항체 및 이의 용도
US9358235B2 (en) * 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
CA2960574C (en) * 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Pyrazolopyrimidine derivatives as nik inhibitors
MY186368A (en) * 2015-07-20 2021-07-16 Genzyme Corp Colony stimulating factor-1 receptor (csf-1r) inhibitors
US20200071326A1 (en) * 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors

Also Published As

Publication number Publication date
EP3950063A4 (en) 2022-11-30
MX2021011923A (es) 2021-11-03
CN113613729A (zh) 2021-11-05
JPWO2020203950A1 (enrdf_load_stackoverflow) 2020-10-08
BR112021019050A2 (pt) 2021-11-30
KR20210146320A (ko) 2021-12-03
WO2020203950A1 (ja) 2020-10-08
US20220162206A1 (en) 2022-05-26
EP3950063A1 (en) 2022-02-09
CA3134937A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
SG11202110922QA (en) Camptothecin derivatives
IL275365A (en) 6-Azaindole compounds
ZA202204675B (en) New methylquinazolinone derivatives
GB202201999D0 (en) Interleukin-2 Derivative
IL289197A (en) History of 2-hydroxycycloalkane-1-carbamoyl
IL289589A (en) New methods
IL290815A (en) History of alpha-d-galactopyranoside
PL4077334T3 (pl) Pochodne furoindazolu
EP3885347A4 (en) DIHYDROPYRROLOPYRAZOLE DERIVATIVE
IL290964A (en) A 2-aminoquinazolinone derivative
SG11202012594RA (en) Spirochromane derivatives
IL288950A (en) History of pyridine-3-yl
LT3796975T (lt) Sulfonilaminobenzamido dariniai
SG11202007979UA (en) Dihydrochromene derivative
SG11202006837XA (en) Dihydroindolizinone derivative
GB201919210D0 (en) Dihydro-cyclopenta-isoquinoline derivatives
GB201919213D0 (en) Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds
SG11202109997PA (en) Novel azaindole derivative
GB201914325D0 (en) Novel meethod
ZA202200181B (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
GB201911764D0 (en) Novel Methods
GB201911762D0 (en) Novel methods
GB201917413D0 (en) Zeolite
GB201901043D0 (en) Novel methods
GB201806948D0 (en) Derivatives